rosiglitazone has been researched along with cabozantinib in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benrimoh, N; Engel, C; Holland, J; Lacy, S; Miles, D; Nguyen, L; O'Reilly, T | 1 |
1 trial(s) available for rosiglitazone and cabozantinib
| Article | Year |
|---|---|
Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
Topics: Anilides; Antineoplastic Agents; Area Under Curve; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Half-Life; Humans; Hypoglycemic Agents; Ketoconazole; Microsomes, Liver; Pyridines; Receptor Protein-Tyrosine Kinases; Rifampin; Rosiglitazone; Thiazolidinediones | 2015 |